Skip to main content
    I

    Immunitybio Inc (IBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.98
    -0.04 (-0.66%)

    Market Cap: $6.40B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Immunitybio Inc (IBRX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Immunitybio (IBRX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Immunitybio reported EPS of -$0.10, below the -$0.08 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -3.36%

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.19 - -$0.07
    6 analysts
    Revenue Consensus
    $57.73M
    Range$53.21M - $61.53M
    6 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.08
    Range-$0.08 - -$0.08
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago-$0.09+11.1%
    30d ago-$0.09+11.1%
    7d ago-$0.09+11.1%
    Current-$0.08
    Revenue Consensus
    $69.22M
    Range$69.22M - $69.22M
    1 analysts

    Next Report

    IBRX has an expected report date of Feb 22, 2027.

    IBRX Earnings Call

    The latest IBRX earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, IBRX beat 19, missed 18 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $48.84M, up 52.3% from $32.06M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.10-$0.08-$0.09 - $0.00-25.00%MissN/A31 up, 0 downNov 5, 2026$48.84M
    Jun 30, 2026-$0.08-$0.09N/A+11.11%BeatN/A11 up, 1 downAug 4, 2026$51.24M
    Mar 31, 2026-$0.08-$0.07-$0.09 - -$0.05-14.29%MissN/A31 up, 1 downMay 7, 2026$44.21M
    Dec 31, 2025-$0.06-$0.11-$0.14 - -$0.07+45.75%BeatN/A3N/AFeb 23, 2026$64.71M
    Sep 30, 2025-$0.07-$0.10-$0.12 - -$0.09+30.00%BeatN/A31 up, 0 downNov 4, 2025$32.06M
    Jun 30, 2025-$0.10-$0.10-$0.11 - -$0.090.00%In lineN/A21 up, 0 downAug 5, 2025$26.43M
    Mar 31, 2025-$0.15-$0.16N/A+6.25%BeatN/A20 up, 1 downMay 12, 2025$16.52M
    Dec 31, 2024-$0.08-$0.13-$0.13 - -$0.13+38.46%BeatN/A10 up, 0 downMar 3, 2025$8.60M
    Sep 30, 2024-$0.12-$0.18-$0.19 - -$0.17+33.33%BeatN/A30 up, 0 downNov 12, 2024$6.11M
    Jun 30, 2024-$0.20-$0.15N/A-33.33%MissN/AN/A0 up, 0 downAug 12, 2024N/A
    Mar 31, 2024-$0.20-$0.16-$0.16 - -$0.16-25.00%MissN/A10 up, 0 downMay 9, 2024$40000
    Dec 31, 2023-$0.38-$0.18-$0.18 - -$0.18-111.11%MissN/A10 up, 0 downMar 19, 2024$139000
    Sep 30, 2023-$0.19-$0.18N/A-5.56%MissN/AN/A0 up, 0 downNov 8, 2023$82000
    Jun 30, 2023-$0.32-$0.23-$0.26 - -$0.21-39.13%MissN/A20 up, 0 downAug 8, 2023$41000
    Mar 31, 2023-$0.27-$0.27N/A0.00%In lineN/AN/A0 up, 0 downMay 11, 2023$360000
    Dec 31, 2022-$0.27-$0.22-$0.22 - -$0.22-22.73%MissN/A10 up, 0 downMar 1, 2023$73000
    Sep 30, 2022-$0.28-$0.21-$0.26 - -$0.20-33.33%MissN/A20 up, 0 downNov 9, 2022$118000
    Jun 30, 2022-$0.24-$0.24N/A0.00%In lineN/AN/A0 up, 0 downAug 8, 2022$35000
    Mar 31, 2022-$0.26-$0.22-$0.22 - -$0.22-18.18%MissN/A10 up, 0 downMay 10, 2022$14000
    Dec 31, 2021-$0.23-$0.21-$0.21 - -$0.21-9.52%MissN/A10 up, 0 downMar 1, 2022$390000
    Sep 30, 2021-$0.22-$0.20-$0.20 - -$0.20-10.00%MissN/A1N/ANov 12, 2021$66000
    Jun 30, 2021-$0.23-$0.12N/A-91.67%MissN/AN/AN/AAug 12, 2021$339000
    Mar 31, 2021-$0.21-$0.41-$0.41 - -$0.41+48.78%BeatN/A1N/AMay 14, 2021$139000
    Dec 31, 2020-$0.30-$0.18N/A-66.67%MissN/AN/AN/AMar 4, 2021N/A
    Sep 30, 2020-$0.20-$0.18N/A-11.11%MissN/AN/AN/ANov 9, 2020$151000
    Jun 30, 2020-$0.20-$0.19N/A-5.26%MissN/AN/AN/AAug 7, 2020$436000
    Mar 31, 2020-$0.19-$0.17N/A-11.76%MissN/AN/AN/AMay 11, 2020$165000
    Dec 31, 2019-$0.16-$0.20N/A+20.00%BeatN/AN/AN/AMar 25, 2020$2.17M
    Sep 30, 2019-$0.16-$0.18N/A+11.11%BeatN/AN/AN/ANov 5, 2019$12000
    Jun 30, 2019-$0.17-$0.24N/A+29.17%BeatN/AN/AN/AAug 6, 2019$17000
    Mar 31, 2019-$0.22-$0.23N/A+4.35%BeatN/AN/AN/AMay 8, 2019$5000
    Dec 31, 2018-$0.22-$0.31N/A+29.03%BeatN/AN/AN/AMar 13, 2019$7000
    Sep 30, 2018-$0.30-$0.37N/A+18.92%BeatN/AN/AN/ANov 7, 2018$31000
    Jun 30, 2018-$0.35-$0.38N/A+7.89%BeatN/AN/AN/AAug 6, 2018$4000
    Mar 31, 2018-$0.35-$0.34N/A-2.94%MissN/AN/AN/AMay 7, 2018$5000
    Dec 31, 2017-$0.31-$0.33N/A+6.06%BeatN/AN/AN/AMar 12, 2018$12000
    Sep 30, 2017-$0.30-$0.32N/A+6.25%BeatN/AN/AN/ANov 7, 2017$8000
    Jun 30, 2017-$0.29-$0.31N/A+6.45%BeatN/AN/AN/AAug 7, 2017$14000
    Mar 31, 2017-$0.30-$0.36N/A+16.67%BeatN/AN/AN/AMay 8, 2017$11000
    Dec 31, 2016-$0.29-$0.43N/A+32.56%BeatN/AN/AN/AMar 15, 2017$14000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.38, after -$0.60 the year before. It was -$1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.38N/A
    Dec 31, 2024-$0.60N/A
    Dec 31, 2023-$1.16N/A
    Dec 31, 2022-$1.05N/A
    Dec 31, 2021-$0.89N/A
    Dec 31, 2020-$0.89N/A
    Dec 31, 2019-$0.71N/A
    Dec 31, 2018-$1.22N/A
    Dec 31, 2017-$1.20N/A
    Dec 31, 2016-$1.47N/A

    Earnings Calls

    The only earnings call listed below, 2025Q4 for the period ended Dec 31, 2025, runs about 7,700 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20257,6928

    2025Q4 Earnings Call

    Opening remarks

    Patrick Soon-Shiong Founder, Executive Chairman, and Global Chief Scientific and Medical Officer Welcome, everybody, to our conference call, and it's really a seminal moment for the company where on an annual basis, we provide an update. But this year, it's really very special because not only do we have an approval, we have the commercial results that we can show that's operational excellence on execution. We will have Rich Adcock, the CEO, present that. But before we go into the commercial launch of ANKTIVA, I would like to take this opportunity to really give a little context and history of ImmunityBio, its evolution, and more importantly, the strategy that we've embarked on since 2015 when NantKwest went public and then all the way to its merger with NantCell and the public offering of ImmunityBio. I want to indulge in doing so because I think it explains to our audience the platform of the products that make up the BioShield platform. On the one hand, we have ANKTIVA, which is truly the backbone of this entire BioShield platform. And the reason it's a backbone is: one, it is approved; two, its mechanism of action is unique. It's the first time in medical history, quite literally, that there is a cytokine molecule called IL-15 that is now approved that one has been identified by the National Cancer Institute as the #1 molecule to cure cancer as far back as 2007. And by 2024, the FDA affirmed this IL-15 by stating in the package insert, its mechanism of action is to stimulate the NK cells, CD4, CD8 T cells, and memory T cells without upregulating Treg cells. That's a mouthful. But that mouthful as a backbone serves as the foundation to take ANKTIVA and combine it with standard of care or combine it with our natural killer cell therapy and combine it all with the adenovirus. Most importantly, it serves as a backbone to treat this condition, which we will talk about called lymphopenia. So again, welcome to all. I will take the first opportunity to present the evolution and history of ImmunityBio and how through our ambition is to actually truly make a different impact in patients with cancer, patients with infectious disease, and patients with lymphopenia. After my presentation, I will turn the call over to Richard Adcock, the CEO, to discuss the current commercial status of the company, and then we will open it up for questions. I would like to provide some context.

    Frequently Asked Questions About IBRX

    When is Immunitybio's next earnings date?

    Immunitybio's next earnings report is expected for Feb 22, 2027.

    Did IBRX beat earnings estimates last quarter?

    No. Immunitybio reported EPS of -$0.10 for the quarter ended Sep 30, 2026, below the -$0.08 estimate by 25.00%.

    What EPS do analysts expect from IBRX next quarter?

    The consensus EPS estimate for Immunitybio for the quarter ending Dec 31, 2026 is -$0.13 from 6 analysts, with estimates from -$0.19 to -$0.07.

    How often does IBRX beat earnings estimates?

    Immunitybio beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +11.54%.